Citigroup Maintains Buy Rating, $85 PT for Watson Pharmaceuticals
In a company update issued earlier today, Citigroup Inc. maintained its Buy rating and $85.00 price target for Watson Pharmaceuticals, Inc. (NYSE: WPI).
Citigroup said it made its decisions “assuming the company trades at a forward P/E multiple of ~10x our 2013E NEWCO cash EPS estimate of $8.49, which is below WPI's 10-year historical median (16x) and average (17x) forward P/E multiple. Watson is a strong domestic generics company with high potential for international growth after the Arrow and Specifar acquisitions and with attractive specialty pharmaceuticals & distribution segments. Watson's performance is contingent on the successful integration of Specifar, Watson's ability to leverage the Arrow/Specifar/moksha8 platform for international expansion, its ability to realize benefits from its global supply chain initiative, generic opportunities that could meaningfully drive upside for its generic business as well as the execution on the uptake of key branded products.”
Watson Pharmaceuticals, Inc. closed on Friday at $76.16.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.